- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06785012
En studie för att undersöka effekten av JNJ-89495120 vid behandling av allvarlig depressiv sjukdom (Moonlight-1)
En randomiserad, dubbelblind, multicenter, placebokontrollerad, Proof-of-Concept-studie för att utvärdera effektiviteten, säkerheten och tolerabiliteten av JNJ-89495120 som monoterapi hos vuxna deltagare med major depressiv sjukdom (MDD)
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Alabama
-
Huntsville, Alabama, Förenta staterna, 35801
- UAB Huntsville Regional Medical Campus
-
-
Arizona
-
Chandler, Arizona, Förenta staterna, 85224
- Chandler Clinical Trials
-
Phoenix, Arizona, Förenta staterna, 85012
- IMA Clinical Research PC Phoenix
-
Tucson, Arizona, Förenta staterna, 85724
- University of Arizona
-
Tucson, Arizona, Förenta staterna, 85704
- Noble Clinical Research
-
-
California
-
Bellflower, California, Förenta staterna, 90706
- CI Trials
-
Encino, California, Förenta staterna, 91316
- Wake Research PRI Encino
-
Garden Grove, California, Förenta staterna, 92844
- National Institute Of Clinical Research
-
Newport Beach, California, Förenta staterna, 92660
- WR-Newport Beach
-
Orange, California, Förenta staterna, 92866
- ATP Clinical Research
-
Redlands, California, Förenta staterna, 92374
- Anderson Clinical Research
-
San Diego, California, Förenta staterna, 92103
- Artemis Institute for Clinical Research
-
San Jose, California, Förenta staterna, 95124
- Lumos Clinical Research Center LLC
-
Santa Ana, California, Förenta staterna, 92705
- Syrentis Clinical Research
-
Temecula, California, Förenta staterna, 92591
- Inland Psychiatric Medical Group Inc
-
Walnut Creek, California, Förenta staterna, 94596
- Sunwise Clinical Research
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80209
- Mountain View Clinical Research
-
-
Florida
-
Fort Myers, Florida, Förenta staterna, 33912
- Gulfcoast Medical Research Center
-
Hollywood, Florida, Förenta staterna, 33021
- The Medici Medical Research
-
Homestead, Florida, Förenta staterna, 33030
- Advanced Research Institute of Miami
-
Maitland, Florida, Förenta staterna, 32751
- K2 Medical Research
-
Miami, Florida, Förenta staterna, 33126
- Pharmax Research Clinic Inc
-
Miami, Florida, Förenta staterna, 33135
- Wellness Research Center
-
Pembroke Pines, Florida, Förenta staterna, 33024
- Best Choice Medical and Research Service
-
Tampa, Florida, Förenta staterna, 33629
- Interventional Psychiatry of Tampa Bay
-
West Palm Beach, Florida, Förenta staterna, 33407
- Health Synergy Clinical Research
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30328
- Synexus Clinical Research US Inc
-
Decatur, Georgia, Förenta staterna, 30030
- iResearch Atlanta LLC
-
Snellville, Georgia, Förenta staterna, 30078
- Accelerated Clinical Research Group LLC
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- University of Chicago Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Indiana University IU Health
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 70115
- DelRicht Research
-
-
Maryland
-
Gaithersburg, Maryland, Förenta staterna, 20877
- CBH Health
-
-
Massachusetts
-
Worcester, Massachusetts, Förenta staterna, 01655
- University of Massachusetts Medical School
-
-
New York
-
Brooklyn, New York, Förenta staterna, 11229
- Integrative Clinical Trials LLC
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45219
- University of Cincinnati
-
Cincinnati, Ohio, Förenta staterna, 45215
- Patient Priority Clinical Sites LLC
-
Columbus, Ohio, Förenta staterna, 43210
- OSU Department of Psychiatry and Behavioral Health
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73116
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- University of Pennsylvania
-
-
South Carolina
-
North Charleston, South Carolina, Förenta staterna, 29405
- Coastal Carolina Research Center
-
-
Texas
-
McKinney, Texas, Förenta staterna, 75071
- Revival Research Institute LLC
-
-
Utah
-
Clinton, Utah, Förenta staterna, 84015
- Alpine Research Organization
-
-
Washington
-
Everett, Washington, Förenta staterna, 98201
- Core Clinical Research
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
- Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
- Were first diagnosed with depression before the age of 55
- Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
- Have taken 0, 1, or 2 treatments for depression in your current episode
- Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening
Exclusion Criteria:
- Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
- Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
- Post-traumatic stress disorder within the past three years of screening
- Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
- History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
- Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm 1: JNJ-89495120 Dose A
Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study. |
JNJ-89495120 will be administered. |
|
Experimentell: Arm 2: JNJ-89495120 Dose A and Dose B
Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study. |
JNJ-89495120 will be administered. |
|
Placebo-jämförare: Arm 3: Placebo Group
Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study. |
Placebo will be administered. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
Tidsram: Baseline up to Day 5
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline up to Day 5
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline in MADRS Total Score to Day 2
Tidsram: Baseline up to Day 2
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline up to Day 2
|
|
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
Tidsram: Baseline up to Day 2 and Day 5
|
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity. |
Baseline up to Day 2 and Day 5
|
|
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
Tidsram: Baseline up to Day 5
|
The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology. |
Baseline up to Day 5
|
|
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
Tidsram: Baseline up to Day 5
|
The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21). |
Baseline up to Day 5
|
|
Number of Participants with Adverse Events (AEs)
Tidsram: Up to approximately 18 weeks
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. |
Up to approximately 18 weeks
|
|
Number of Participants with Abnormalities in Vital Signs Parameters
Tidsram: Up to approximately 18 weeks
|
Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Tidsram: Up to approximately 18 weeks
|
Participants with 12-lead ECG abnormalities will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants With Abnormalities in Laboratory Parameters
Tidsram: Up to approximately 18 weeks
|
Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported. |
Up to approximately 18 weeks
|
|
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
Tidsram: Up to approximately 18 weeks
|
Participants with changes in weight/BMI will be reported. |
Up to approximately 18 weeks
|
|
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
Tidsram: Up to approximately 18 weeks
|
The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline. |
Up to approximately 18 weeks
|
|
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
Tidsram: From Baseline up to 4 weeks
|
The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials. |
From Baseline up to 4 weeks
|
|
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
Tidsram: From Baseline up to 4 weeks
|
The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds. |
From Baseline up to 4 weeks
|
|
Plasma Concentrations of JNJ-89495120
Tidsram: Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13
|
Plasma concentrations of JNJ-89495120 will be reported. |
Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13
|
Samarbetspartners och utredare
Utredare
- Studierektor: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 89495120MDD2001
- 89495120MDD2001 (Annan identifierare: Janssen Research & Development, LLC)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .